2상모집 중단 (진행 중)
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
연구 개요
The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease. The goal of the study is to determine if Dostarlimab therapy alone is an effective treatment that can allow participants to avoid chemotherapy, radiation, and surgery.
- 스폰서
- 리드: GSK
- 적응증
- Neoplasms, Rectal
- 중재
- Dostarlimab
- 목표 등록
- 154명
- 시작일
- 2023-04-03
- 완료(예정)
- 2029-10-11
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.